Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

This study is collecting data on treatment outcomes for patients with lymphoma who develop a serious and potentially life-threatening condition called HLH (hemophagocytic lymphohistiocytosis) — a severe inflammatory response where the immune system attacks the body's own tissues. **You may be eligible if...** - You have lymphoma and have developed HLH, meeting at least 5 of 8 standard diagnostic criteria (HLH-2004) - Or you have very high levels of specific blood markers (sCD25 and ferritin) that indicate HLH **You may NOT be eligible if...** - Your HLH developed more than 1 month after your lymphoma diagnosis (for aggressive lymphoma types) - Your treatment and response records are incomplete Talk to your doctor to see if this trial is right for you.